Submit Manuscript    >>    Login | Register

Left atrial thrombosis despite Dabigatran therapy


Dabigatran is a novel anticoagulation which has been approved as an alternative to warfarin therapy for non-valvular atrial fibrillation. Use of Dabigatran for approved indications as well as off label use has dramatically increased after Federal Drug Administration (FDA) approval. Our patient had left atrial thrombosis even after being on Dabigatran for more than one month which raises question about safety and efficacy of use of dabigatran around cardioversion and ablation.

Credits: Anil Pandit; Fayaz A Hakim; Komandoor Srivathsan; John J Lynch



Biosense Webster
event date
Introduction to AFib
Ablation Specialist

View Ablation Specialists